
Jane Lowe Meisel, MD
255 posts

Jane Lowe Meisel, MD
@jane_meisel
Medical oncologist @WinshipAtEmory specializing in treatment of and research to improve the care of patients with breast and gynecologic cancers. #bcsm #gynsm

















After being announced to be positive, the TROPION-Breast01 phase 3 trial officially joins the already stellar list of abstracts planned to be presented at #ESMO23! #bcsm @myESMO


A new Trop2 ADC is about to become available for patients with HR+/HER2- MBC. In #TB01, datopotamab deruxtecan (Dato-DXd) improved PFS over chemotherapy, with a trend towards improved overall survival. All grade ILD rates seen in the trial were low. #bcsm astrazeneca.com/media-centre/p…


🌍TROPiCS-02🌍 HR+ mBC endocrine-R ⚠️ highly pretreated ❗️unmet need 🚦 ✅OS 14·4 mo vs 11·2 mo HR 0·79 (irresp Trop-2 exp) ✅ORR Saci vs CT ➡️OR 1·63 ✅TTD and QoL 4·3 mo vs 3·0 mo ➡️HR 0·75 and fatigue 2·2 mo vs 1·4 mo➡️HR 0·73 @Oncoalert #OncoalertAF thelancet.com/journals/lance…

















A new treatment paradigm for metastatic HER2+ BC. Nice discussion of destiny breast 04 by Shanu Modi. @OncoAlert @myESMO #esmo2021








